A robust targeted sequencing approach for low input and variable quality DNA from clinical samples

By | Industry Publications | No Comments

Next-generation deep sequencing of gene panels is being adopted as a diagnostic test to identify actionable mutations in cancer patient samples. However, clinical samples, such as formalin-fixed, paraffin-embedded specimens, frequently provide low quantities of degraded, poor quality DNA. To overcome these issues, many sequencing assays rely on extensive PCR amplification leading to an accumulation of bias and artifacts.

Read More

Rapidly Evolving Cancer Genomics IP Landscape

By | TOMA News | No Comments

Cancer genomics technology is rapidly advancing worldwide — creating a complex, evolving, and valuable intellectual property landscape that will impact how this technology will be clinically implemented. Clinical pathology laboratories need to understand both the next-generation sequencing technologies and their…

Read More